Healthcare Industry News:  Sanofi-aventis 

Biopharmaceuticals Generics Litigation

 News Release - February 27, 2006

King Pharmaceuticals Reports Agreement on Dismissal of Altace(R) Patent Litigation

BRISTOL, Tenn., Feb. 27 (HSMN NewsFeed) -- King Pharmaceuticals, Inc. (NYSE: KG ) today reported that King, Aventis Pharma Deutschland GmbH (now known as Sanofi-aventis Deutschland GmbH) and Cobalt Pharmaceuticals, Inc. have entered into an agreement to dismiss the pending litigation relating to the enforcement of U.S. Patent Nos. 5,061,722 ("the '722 Patent") and 5,403,856 ("the '856 Patent"). The parties agreed that, subject to certain conditions, within 38 days of signing the agreement, King, Aventis and Cobalt will submit a joint stipulation dismissing without prejudice the litigation before the U.S. District Court for the District of Massachusetts.

Cobalt had sought to market generic versions of AltaceŽ (ramipril) before expiration of the '722 Patent and '856 Patent which relate to AltaceŽ by filing an Abbreviated New Drug Application.

About AltaceŽ

AltaceŽ is marketed by Monarch Pharmaceuticals, Inc., a wholly owned subsidiary of King Pharmaceuticals, and Wyeth Pharmaceuticals in the United States and Puerto Rico pursuant to a co-promotion agreement.

AltaceŽ is a leading branded ACE inhibitor with multiple indications. AltaceŽ is indicated for the treatment of hypertension. AltaceŽ has also been shown to reduce the risk of death in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Based upon the results of the landmark HOPE trial, AltaceŽ is also indicated in patients 55 years or older at high risk of developing a major cardiovascular event either because of a history of coronary artery disease, stroke or peripheral vascular disease or because of diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of stroke, myocardial infarction, or death from cardiovascular causes. AltaceŽ can be used in addition to other needed treatments (such as antihypertensive, antiplatelet or lipid-lowering therapies).

Prescription AltaceŽ is not for everyone. AltaceŽ may cause swelling of the mouth, tongue, or throat, which could cause extremely serious risk and requires immediate medical care. AltaceŽ may lower blood sugar if taken for diabetes. A physician should be contacted if one experiences symptoms of low blood sugar such as sweating or shakiness. Common side effects include persistent dry cough, dizziness, and light-headedness due to low blood pressure. AltaceŽ should not be taken during pregnancy, as death or injury to an unborn child may result, or if serious side effects related to previous ACE inhibitors have occurred.

For a copy of the AltaceŽ prescribing information, please visit

About King Pharmaceuticals

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.

Source: King Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.